MK0974 Long Term Safety Study

The purpose of this study is to investigate the safety and tolerability of MK0974 in the long-term treatment of acute migraine...

Date First Received: February 28, 2007

Last Updated: August 17, 2007

Verified by: Merck, August 2007

Clinical Trial Phase: Phase 3 | Start Date: March 2007

Overall Status: Active, not recruiting

Estimated Enrollment: 900

Brief Summary

Official Title: “Long-Term Intermittent Treatment of Acute Migraine With MK0974”

Condition Keyword(s):

The purpose of this study is to investigate the safety and tolerability of MK0974 in the long-term treatment of acute migraine.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Intervention(s) in this Clinical Trial

  • Drug: MK0974 / Duration of Treatment: 1 Years
  • Drug: Comparator: rizatriptan benzoate / Duration of Treatment: 1 Years

Outcome Measures for this Clinical Trial

Primary Measures

  • Adverse experiences, laboratory values, ECGs, and vital signs
    • Time Frame: During the study

Secondary Measures

  • Pain freedom
    • Time Frame: 2 hours post-dose

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Patient has at least 1 year history of migraine (with or without aura)
  • Females of child bearing potential must use acceptable contraception throughout trial
  • Patient is in general good health based on screening assessment

Exclusion Criteria:

  • Patient is pregnant/breast-feeding (or is a female expecting to conceive during study period)
  • Patient has history or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or HIV disease
  • Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
  • Patient has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption
  • Patient has a history of cancer within the last 5 years

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Merck

Overall Clinical Trial Officials and Contacts

Medical Monitor Study Director Merck  

Additional Information

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00443209

Study ID Number: 2006_524

ClinicalTrials.gov Identifier: NCT00443209

Health Authority: United States: Food and Drug Administration

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.